Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Capital Expenditures (2020 - 2025)

Mirum Pharmaceuticals has reported Capital Expenditures over the past 6 years, most recently at $600000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $600000.0 for Q4 2025, up 2900.0% from a year ago — trailing twelve months through Dec 2025 was $954000.0 (down 3.93% YoY), and the annual figure for FY2025 was $954000.0, down 3.93%.
  • Capital Expenditures for Q4 2025 was $600000.0 at Mirum Pharmaceuticals, up from $187000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for MIRM hit a ceiling of $779000.0 in Q2 2024 and a floor of $3000.0 in Q1 2021.
  • Median Capital Expenditures over the past 5 years was $41000.0 (2023), compared with a mean of $147375.0.
  • Biggest five-year swings in Capital Expenditures: plummeted 96.94% in 2021 and later surged 7966.67% in 2022.
  • Mirum Pharmaceuticals' Capital Expenditures stood at $3000.0 in 2021, then surged by 7966.67% to $242000.0 in 2022, then crashed by 71.9% to $68000.0 in 2023, then plummeted by 70.59% to $20000.0 in 2024, then surged by 2900.0% to $600000.0 in 2025.
  • The last three reported values for Capital Expenditures were $600000.0 (Q4 2025), $187000.0 (Q3 2025), and $126000.0 (Q2 2025) per Business Quant data.